نتایج جستجو برای: allogeneic bmt

تعداد نتایج: 28117  

Journal: :Blood 2006
Alejo Chorny Elena Gonzalez-Rey Amelia Fernandez-Martin Doina Ganea Mario Delgado

Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow transplantation (BMT) for the treatment of leukemia and other immunogenetic disorders. The use of tolerogenic dendritic cells (DCs) that induce the generation/activation of regulatory T (Tr) cells for the treatment of acute GVHD following allogeneic BMT has been recen...

2002
Katharine A. Whartenby Erin E. Straley Heeje Kim Frederick Racke Vivek Tanavde Kevin S. Gorski Linzhao Cheng Drew M. Pardoll Curt I. Civin

Fas-mediated apoptosis is a major physiologic mechanism by which activated T cells are eliminated after antigen-stimulated clonal expansion generates a specific cellular immune response. Because activated T cells are the major effectors of allograft rejection, we hypothesized that genetically modifying allogeneic bone marrow (BM) cells prior to transplantation could provide some protection from...

2011
Shuichiro Takashima Masanori Kadowaki Kazutoshi Aoyama Motoko Koyama Takeshi Oshima Kazuma Tomizuka Koichi Akashi Takanori Teshima

Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation (BMT), and damage to the gastrointestinal (GI) tract plays a critical role in amplifying systemic disease. Intestinal stem cells (ISCs) play a pivotal role not only in physiological tissue renewal but also in regeneration of the intestinal epithelium after injury. In this study, we have discovered...

Journal: :Journal of immunology 2013
Christian M Capitini Nicole M Nasholm Brynn B Duncan Martin Guimond Terry J Fry

Tumor-targeted vaccines represent a strategy to enhance the graft-versus-leukemia effect after allogeneic blood and marrow transplantation (BMT). We have previously shown that graft-versus-host disease (GVHD) can negatively impact quantitative responses to vaccines. Using a minor histocompatibility Ag-mismatched BMT (B6 → B6 × C3H.SW) followed by adoptive transfer of HY-specific T cells and HY-...

2010
Takashi Ushiki Shinae Kizaka-Kondoh Eishi Ashihara Shotaro Tanaka Masayoshi Masuko Hideyo Hirai Shinya Kimura Yoshifusa Aizawa Taira Maekawa Masahiro Hiraoka

BACKGROUND Many diseases associated with bone marrow transplantation (BMT) are caused by transplanted hematopoietic cells, and the onset of these diseases occurs after homing of donor cells in the initial phase after BMT. Noninvasive observation of donor cell homing shortly after transplantation is potentially valuable for improving therapeutic outcomes of BMT by diagnosing the early stages of ...

Journal: :Leukemia & lymphoma 1993
K C Anderson J Andersen R Soiffer A S Freedman S N Rabinowe M J Robertson N Spector K Blake C Murray A Freeman

Forty patients with plasma cell dyscrasias underwent high-dose chemoradiotherapy and either anti-B-cell monoclonal antibody (MoAb)-treated autologous, anti-T-cell MoAb-treated HLA-matched sibling allogeneic or syngeneic bone marrow transplantation (BMT). The majority of patients had advanced Durie-Salmon stage myeloma at diagnosis, all were pretreated with chemotherapy, and 17 had received prio...

Journal: :Internal medicine 1998
M Harada

BMT, including 1) rapid hematopoietic engraftment, 2) less requirement for blood transfusion, antibiotic therapy and hospitalization days, and 3) avoidance of.risks and discomfort associated with general anesthesia for collecting hematopoietic stem cells (2). Taking these advantages into consideration, the use of PBSCwas applied for syngeneic and allogeneic transplantation in the early 1990' s....

Journal: :Blood 1995
P Ljungman N Johansson J Aschan H Glaumann B Lönnqvist O Ringdén E Sparrelid A Sönnerborg J Winiarski G Gahrton

A total of 161 patients transplanted between 1978 and 1991 and who had survived at least 2 years after allogeneic bone marrow transplantation (BMT) were studied. Of 161 surviving patients, 28 (17.4%) were positive for hepatitis C virus (HCV) either by serology or polymerase chain reaction (PCR). Twenty-five patients were positive for HCV RNA by PCR, and 26 of the 28 patients had HCV antibodies ...

Journal: :Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002
Stephanie k Lee E Francis Cook Robert Soiffer Joseph H Antin

Chronic GVHD (cGVHD) affects 30% to 90% of surviving allogeneic transplant recipients. Thus far, no quality-of-life instruments have been developed to measure the effect of this common complication of allogeneic transplantation on patients' functioning and well-being. Using a prospective cohort of 107 patients with active cGVHD who completed the symptom scale at enrollment and at intervals of 3...

Journal: :Blood 1997
D J Diamond J York J Y Sun C L Wright S J Forman

The development of a protective cellular immune response against human cytomegalovirus (HCMV) is the most important determinant of recovery from HCMV infection after allogeneic bone marrow transplantation (BMT). The ultimate aim of our study is to develop an antigen-specific and peptide-based vaccine strategy against HCMV in the setting of BMT. Toward this end we have studied the cellular immun...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید